Terapia con Células Car-t Anti-bcma ¿Resuelve la Evasión Inmune en el Mieloma Múltiple?
Palabras clave:
mieloma múltiple, células plasmáticas, receptor de antígeno quimérico, antígeno de maduración de linfocitos B
Resumen
El mieloma múltiple (MM) constituye una neoplasia hematológica que se caracteriza por la proliferación sin control de células plasmáticas en la médula ósea. El tratamiento ha dado grandes avances a lo largo de estos últimos años, sin embargo, la mayoría de los pacientes han recaído volviéndose una enfermedad incurable, sobre todo en aquellos que desarrollan resistencia a los medicamentos convencionales. Un aspecto importante para que progrese la enfermedad es la evasión inmune por parte de las células tumorales, que les permite persistir en el microambiente tumoral a pesar de existir una respuesta inmunitaria. Esta revisión narrativa de la literatura de los mecanismos de escape inmune en mieloma múltiple analiza el efecto de la terapia CAR-T anti-BCMA, los desafíos y mecanismos de evasión después del tratamiento, para determinar estrategias que mejoren la eficacia de la terapia con células CAR-T anti BCMA frente a la disminución o pérdida de antígeno como estrategia de evasión después del tratamiento. En conclusión, la terapia con células T modificadas genéticamente, conocida como CAR-T (receptor quimérico de antígeno), ha surgido como un tratamiento prometedor en MM, en particular la terapia dirigida contra el antígeno BCMA (antígeno de maduración de células B). La focalización multiantigénica de las células CAR-T anti BCMA, con dominios de acción biespecíficos, o la combinación con otras terapias mejora las respuestas y la eficacia de la terapia.
Descargas
La descarga de datos todavía no está disponible.
Citas
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. El, Bhat, A. A. & Uddin, S. (2020). Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. In International Journal of Molecular Sciences (Vol. 21, Issue 14, pp. 1–24). MDPI AG. https://doi.org/10.3390/ijms21145002
Basudhar, D., Descalzi-Montoya, D., Tang, H., Wang, M., Wu, F., Bergsagel, P. L., Leleu, X., Hosseyni, D., Chaudhry, M., Martin, N. & Thompson, E. G. (2024). Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis. Blood, 144(Supplement 1), 3382–3382.
https://doi.org/10.1182/blood-2024-198740
Beatty, G. L. & Gladney, W. L. (2015). Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 21(4), 687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O’Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., … Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet, 398(10297), 314–324.
https://doi.org/10.1016/S0140-6736(21)00933-8
Botta, C., Mendicino, F., Martino, E. A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A. & Gentile, M. (2021). Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 13(13), 3213.
https://doi.org/10.3390/cancers13133213
Cancer site ranking. (n.d.). Retrieved July 1, 2025, from
https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T. & Kochenderfer, J. N. (2013). B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma. Clinical Cancer Research, 19(8), 2048–2060. https://doi.org/10.1158/1078-0432.CCR-12-2422
Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F. & Asmamaw Dejenie, T. (2022). Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol., 13, 991092.
https://doi.org/10.3389/fimmu.2022.991092
Chen, H., Wang, X., Wang, Y. & Chang, X. (2023). What happens to regulatory T cells in multiple myeloma. Cell Death Discov., 9(1), 468. https://doi.org/10.1038/s41420-023-01765-8
Cheng, Y., Zhang, J., Mu, W., Ye, S., Cheng, J., Zhu, L., Wang, G., Cao, Y., Li, D., Hu, G., Huang, L., Wang, J. & Zhou, J. (2025). Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Molecular Therapy, 33(4), 1535–1551. https://doi.org/10.1016/j.ymthe.2025.02.012
Cho, S. F., Anderson, K. C. & Tai, Y. T. (2018). Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. In Frontiers in Immunology (Vol. 9, Issue AUG). Frontiers Media S.A.
https://doi.org/10.3389/fimmu.2018.01821
Cowan, A. J., Pont, M. J., Sather, B. D., Turtle, C. J., Till, B. G., Libby, E. N., Coffey, D. G., Tuazon, S. A., Wood, B., Gooley, T., Wu, V. Q., Voutsinas, J., Song, X., Shadman, M., Gauthier, J., Chapuis, A. G., Milano, F., Maloney, D. G., Riddell, S. R. & Green, D. J. (2023). γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. The Lancet Oncology, 24(7), 811–822. https://doi.org/10.1016/S1470-2045(23)00246-2
Duan, D. / W. (2021). The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. PubMed.
https://doi.org/10.3389/fimmu.2021.609421
Dytfeld, D., Dhakal, B., Agha, M., Manier, S., Delforge, M., Kuppens, S., Afifi, S., Deraedt, W., Taraseviciute-Morris, A., Schecter, J. M. & al., et. (2021). Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: a Randomized, Phase 3 Study (CARTITUDE-5). Blood, 138, 1835. https://doi.org/10.1182/blood-2021-146210
FDA. (n.d.). Center for Drug Evaluation, Research. FDA approves idecabtagene vicleucel for multiple myeloma [Internet]. U.S. Food and Drug Administration. FDA; 2024.
Feins, S., Kong, W., Williams, E. F., Milone, M. C. & Fraietta, J. A. (2019). An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. In American Journal of Hematology (Vol. 94, Issue S1, pp. S3–S9). Wiley-Liss Inc.
https://doi.org/10.1002/ajh.25418
Fischer, L., Grieb, N., Platzbecker, U., Vucinic, V. & Merz, M. (2024). CAR T cell therapy in multiple myeloma, where are we now and where are we heading for? In European Journal of Haematology (Vol. 112, Issue 1, pp. 19–27). John Wiley and Sons Inc.
https://doi.org/10.1111/ejh.14051
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B. & Kröger, N. (2020). Development of CAR-T cell therapies for multiple myeloma. Leukemia, 34(9), 2317–2332.
https://doi.org/10.1038/s41375-020-0930-x
Garfall, A. L., Cohen, A. D., Lacey, S. F., Tian, L., Hwang, W.-T., Vogl, D. T., Waxman, A., Lancaster, E., Nelson, A. M., Ferthio, R. & al., et. (2019). Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. Blood, 134. https://doi.org/10.1182/blood-2019-131515
Hamieh, M., Dobrin, A., Cabriolu, A., Van Der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., Li, Z., Cunanan, K. M., Huse, M., Hendrickson, R. C., Wang, X., Rivière, I. & Sadelain, M. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568(7750), 112–116.
https://doi.org/10.1038/s41586-019-1054-1
Hillengass, J., Cohen, A. D., Agha, M. E., Delforge, M., Kerre, T., Roeloffzen, W., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M. S., Scheid, C., Anguille, S., Sonneveld, P., Zweegman, S., Schecter, J. M., De Braganca, K. C., Jackson, C. C., Vlummens, P., Varsos, H., … Van De Donk, N. W. C. J. (2023). The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B). Blood, 142(Supplement 1), 1021. https://doi.org/10.1182/blood-2023-178882
Ho, M., Goh, C. Y., Patel, A., Staunton, S., O’Connor, R., Godeau, M. & Bianchi, G. (2020). Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma Myeloma and Leukemia, 20(10), e752–e768.
https://doi.org/10.1016/j.clml.2020.05.026
Jameson, L., Kasper, D., Longo, D., Fauci, A., Hauser, S. & Loscalzo, J. (2018). Harrison Principios de Medicina Interna (L. Jameson, D. Kasper, D. Longo, A. Fauci, S. Hauser, & J. Loscalzo, Eds.; 20a ed., Vol. 1). Mc Graw Hill Education .
Joshua, D. E., Bryant, C., Dix, C., Gibson, J. & Ho, J. (2019). Biology and therapy of multiple myeloma. In Medical Journal of Australia (Vol. 210, Issue 8, pp. 375–380). John Wiley and Sons Inc. https://doi.org/10.5694/mja2.50129
Joshua, D. E., Vuckovic, S., Favaloro, J., Lau, K. H. A., Yang, S., Bryant, C. E., Gibson, J. & Ho, P. J. (2021). Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. Front. Immunol., 12, 620596. https://doi.org/10.3389/fimmu.2021.620596
Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C. & Caers, J. (2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? In Journal of Hematology and Oncology (Vol. 15, Issue 1). BioMed Central Ltd.
https://doi.org/10.1186/s13045-022-01296-2
Leblay, N., Maity, R., Hasan, F. & Neri, P. (2020). Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. In Frontiers in Oncology (Vol. 10). Frontiers Media S.A. https://doi.org/10.3389/fonc.2020.00636
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., Barakat, E., Poorebrahim, M., Sinha, S., McIntyre, J., M.Y. Chan, A., Wilson, H., Kyman, S., Krishnan, A., Landgren, O., … Bahlis, N. J. (2023). Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med, 29(9), 2295–2306. https://doi.org/10.1038/s41591-023-02491-5
Agila Mocha, R. J., Vivanco Ureña, C. I., León Bravo, F. E., & Reyes Carrión , J. P. (2025). Software Educativos para el Proceso de Enseñanza Aprendizaje de Matemáticas en Bachillerato. Ciencia Y Reflexión, 4(2), 1341–1369. https://doi.org/10.70747/cr.v4i2.334
Urquidez Romero , R., Avitia Sánchez, A., Cano Ramírez , D., Jiménez Montes , L. V., Barranco Merino, G. I., & Reyes Ruvalcaba, D. (2025). Programa de Intervención con un Suplemento Multivitamínico para Mejorar el Estado de Nutrición y Anemia en Niños en Condición de Vulnerabilidad Social de Ciudad Juárez Chihuahua. Ciencia Latina Revista Científica Multidisciplinar, 9(3), 8340-8354. https://doi.org/10.37811/cl_rcm.v9i3.18460
Añapa Quiñónez, P. L., Recalde Páez, J. P., Fey Zalamea, C. D., Rivera Quiñónez, E. D., & Acuri Pacheco, D. A. (2025). Estrategias para la Implementación Efectiva del Aprendizaje Híbrido (Blended Learning) en Instituciones Educativas Rurales del Ecuador: Un Análisis Integral. Ciencia Y Reflexión, 4(2), 1160–1184. https://doi.org/10.70747/cr.v4i2.325
Tenesaca Canchignia , D. C., Canchignia Bonilla, E. L., Remache Guamán, N. V., Guamán Sagñay , H. P., & Hualcopo Duchicela, U. E. (2025). Guía para padres con respecto al uso de dispositivos móviles el niños de nivel preparatorio. Arandu UTIC, 12(2), 287–307. https://doi.org/10.69639/arandu.v12i2.925
Araujo García, D., Chang Espinosa , O. Y., & Pérez Vázquez , D. (2025). Consultoría Estratégica para Mipymes: Estudio de Mercado para Impulsar el Desarrollo Regional en Perote, Veracruz. Estudios Y Perspectivas Revista Científica Y Académica , 5(3), 27–45. https://doi.org/10.61384/r.c.a.v5i3.1328
Simbaña Cabrera, H. A., Haro Jácome, O. F., García-Romero , C. A., & Analuisa García , P. S. (2025). La titulación rural, una propuesta colectiva que evidencia la realidad educativa de las escuelas multigrado. Emergentes - Revista Científica, 5(2), 1–14. https://doi.org/10.60112/erc.v5.i2.385
Cortés Viveros, N., Hernández García, R. A., Galván Sarabia, A., Olivares Galvan, H. R., & Texon Olguin, O. A. (2025). En Busca del Modelo Ideal para Determinar las Variables que Explican el Tiempo de Desempleo en Buscadores Xalapeños. Estudios Y Perspectivas Revista Científica Y Académica , 5(3), 65–81. https://doi.org/10.61384/r.c.a.v5i3.1332
Bernal Parraga, A. P., Salazar Véliz , E. T., Zambrano Lamilla, L. M., Espinoza Jaramillo , S. G., Morales García , C. S., Shinger Hipatia, N. S., & Zapata Calderón , S. J. (2025). Innovaciones Didácticas para Lengua y Literatura Basadas en el Aprendizaje Personalizado y Colaborativo . Revista Científica De Salud Y Desarrollo Humano , 6(2), 01–32. https://doi.org/10.61368/r.s.d.h.v6i2.574
Sabando Suárez, A. A., Vega Guamangate, J. M., García Gallirgos, V. J., & Mora Carpio, W. T. (2025). Impacto del Gasto Social en el Índice de Desarrollo Humano en Ecuador. periodo 2001-2023. Revista Veritas De Difusão Científica, 6(2), 1593–1633. https://doi.org/10.61616/rvdc.v6i2.707
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., De Re, V., Argentiero, A., Silvestris, N., Vacca, A. & Racanelli, V. (2020). Actors on the Scene: Immune Cells in the Myeloma Niche. Front. Oncol., 10, 599098.
https://doi.org/10.3389/fonc.2020.599098
Li, H., Li, J., Wu, J., Shi, Z., Gao, Y., Song, W., Li, J., Li, Z. & Zhang, M. (2023). A second-generation CD38-CAR-T cell for the treatment of multiple myeloma. Cancer Medicine, 12(9), 10804–10815. https://doi.org/10.1002/cam4.5818
Lu, J. & Jiang, G. (2022). The journey of CAR-T therapy in hematological malignancies. Mol Cancer, 21(1), 194. https://doi.org/10.1186/s12943-022-01663-0
Mancuso, K., Barbato, S., Talarico, M., Tacchetti, P., Zamagni, E. & Cavo, M. (2025). Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. Expert Opinion on Biological Therapy, 25(1), 27–46.
https://doi.org/10.1080/14712598.2024.2433518
Mann, H. & Comenzo, R. L. (2022). Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. In OncoTargets and Therapy (Vol. 15, pp. 799–813). Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S305429
Munshi, N. C. / A. (2021). Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. PubMed. https://doi.org/10.1056/NEJMoa2024850
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G. & Gangemi, S. (2017). Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. In Mediators of Inflammation (Vol. 2017). Hindawi Limited.
https://doi.org/10.1155/2017/1852517
Nakamura, K., Smyth, M. J. & Martinet, L. (2020). Cancer immunoediting and immune dysregulation in multiple myeloma. Blood, 136(24), 2731–2740. https://doi.org/10.1182/blood.2020006540
Nasiri, F., Asaadi, Y., Mirzadeh, F., Abdolahi, S., Molaei, S., Gavgani, S. P. & Rahbarizadeh, F. (2024). Updates on CAR T cell therapy in multiple myeloma. Biomark Res, 12(1), 102.
https://doi.org/10.1186/s40364-024-00634-5
O’Neal, J., Ritchey, J. K., Cooper, M. L., Niswonger, J., Sofía González, L., Street, E., Rettig, M. P., Gladney, S. W., Gehrs, L., Abboud, R., Prior, J. L., Haas, G. J., Jayasinghe, R. G., Ding, L., Ghobadi, A., Vij, R. & DiPersio, J. F. (2022). CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia, 36(6), 1625–1634.
https://doi.org/10.1038/s41375-022-01559-4
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V. & Ajebo, G. H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Medical Sciences, 9(1), 3. https://doi.org/10.3390/medsci9010003
Pont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J., Salter, A. I., Hudecek, M., Comstock, M. L., Rajan, A., Patel, B. K. R., Voutsinas, J. M., Wu, Q., Liu, L., Cowan, A. J., Wood, B. L., Green, D. J. & Riddell, S. R. (2019). g-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
http://ashpublications.org/blood/article-pdf/134/19/1585/1505398/bloodbld2019000050.pdf
Poojary, R., Song, A., Song, B., Song, C., Wang, L. & Song, J. (2023). Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review). Mol Clin Oncol, 19(6), 95. https://doi.org/10.3892/mco.2023.2691
Radhakrishnan, V., Golla, U. & Kudva, A. K. (2024). Role of Immune Cells and Immunotherapy in Multiple Myeloma. Life, 14(4), 461. https://doi.org/10.3390/life14040461
Radhakrishnan, S. V, Luetkens, T., Scherer, S. D., Davis, P., Vander Mause, E. R., Olson, M. L., Yousef, S., Panse, J., Abdiche, Y., Li, K. D., Miles, R. R., Matsui, W., Welm, A. L. & Atanackovic, D. (2020). CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun, 11(1), 798. https://doi.org/10.1038/s41467-020-14619-z
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., Lam, L.-P., Morgan, R. A., Friedman, K., Massaro, M., Wang, J., Russotti, G., Yang, Z., Campbell, T., Hege, K., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 380(18), 1726–1737. https://doi.org/10.1056/nejmoa1817226
Ramesh, P., Hui, H. Y. L., Brownrigg, L. M., Fuller, K. A. & Erber, W. N. (2023). Chimeric antigen receptor T-cells: Properties, production, and quality control. In International Journal of Laboratory Hematology (Vol. 45, Issue 4, pp. 425–435). John Wiley and Sons Inc.
https://doi.org/10.1111/ijlh.14121
Rapoport, A. P. (2015). Myeloma escape from immunity: an “inside” job. Blood, 126(12), 1401–1403.
https://doi.org/10.1182/blood-2015-07-659490
Rickert, R. C., Jellusova, J. & Miletic, A. V. (2011). Signaling by the tumor necrosis factor receptor superfamily in B‐cell biology and disease. Immunological Reviews, 244(1), 115–133.
https://doi.org/10.1111/j.1600-065X.2011.01067.x
Rodríguez Otero, P., Ailawadhi, S., Arnulf, B., Patel, K. K., Cavo, M., Nooka, A. K., Manier, S., Callander, N. S., Costa, L., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Weum Abrahamsen, I., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N. S., … Giralt, S. A. (2023). The 65th ASH Annual Meeting Abstracts ORAL ABSTRACTS 705.CELLULAR IMMUNOTHERAPIES: LATE PHASE AND COMMERCIALLY AVAILABLE THERAPIES Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3. In Blood (Vol. 142).
Sadelain, M., Brentjens, R. & Rivière, I. (2013). The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discovery, 3(4), 388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Samur, M. K., Fulciniti, M., Aktas Samur, A., Bazarbachi, A. H., Tai, Y.-T., Prabhala, R., Alonso, A., Sperling, A. S., Campbell, T., Petrocca, F., Hege, K., Kaiser, S., Loiseau, H. A., Anderson, K. C. & Munshi, N. C. (2021). Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun, 12(1), 868.
https://doi.org/10.1038/s41467-021-21177-5
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández De Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., Van De Donk, N. W. C. J., Dytfeld, D., Sidana, S., … Einsele, H. (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379
Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. (2020). B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. In Leukemia (Vol. 34, Issue 4, pp. 985–1005). Springer Nature. https://doi.org/10.1038/s41375-020-0734-z
Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., Mahaki, H., Manoochehri, H., Kalhor, N. & Dama, P. (2024). CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther, 31(5), 667–686.
https://doi.org/10.1038/s41417-024-00750-2
Simon, S. & Riddell, S. R. (2020). Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. Blood Cancer Discovery, 1(2), 130–133. https://doi.org/10.1158/2643-3230.BCD-20-0122
Sun, C., Mahendravada, A., Ballard, B., Kale, B., Ramos, C., West, J., Maguire, T., Mckay, K., Lichtman, E., Tuchman, S., Dotti, G. & Savoldo, B. (2019). Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. In Oncotarget (Vol. 10, Issue 24). www.oncotarget.com
Swan, D., Madduri, D. & Hocking, J. (2024). CAR-T cell therapy in Multiple Myeloma: current status and future challenges. Blood Cancer J., 14(1), 206. https://doi.org/10.1038/s41408-024-01191-8
Teoh, P. J. & Chng, W. J. (2021). CAR T-cell therapy in multiple myeloma: more room for improvement. In Blood Cancer Journal (Vol. 11, Issue 4). https://doi.org/10.1038/s41408-021-00469-5
Usmani, S. Z., Berdeja, J. G., Truppel-Hartmann, A., Casadebaig, M.-L., Wortman-Vayn, H., Shelat, S. G., Novick, S. & Shah, N. (2020). KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma. Blood, 136(Supplement 1), 18–19. https://doi.org/10.1182/blood-2020-139009
Wang, C., Wang, W., Wang, M., Deng, J., Sun, C., Hu, Y. & Luo, S. (2024). Different evasion strategies in multiple myeloma. Front. Immunol., 15, 1346211.
https://doi.org/10.3389/fimmu.2024.1346211
Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., Lim, L., Wong, C. W., Chang, W.-C., Thomas, S. H., Sanchez, J. F., Yang, L., Brown, C. E., Pichiorri, F., Htut, M., Krishnan, A. Y. & Forman, S. J. (2018). Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 24(1), 106–119. https://doi.org/10.1158/1078-0432.CCR-17-0344
Wu, S.-Y., Fu, T., Jiang, Y.-Z. & Shao, Z.-M. (2020). Natural killer cells in cancer biology and therapy. Mol Cancer, 19(1), 120. https://doi.org/10.1186/s12943-020-01238-x
Wudhikarn, K., Mailankody, S. & Smith, E. L. (2020). Future of CAR T cells in multiple myeloma. Hematology, 2020(1), 272–279. https://doi.org/10.1182/hematology.2020000111
Xue, H. Y. & Wei, F. (2024). TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-β in the microenvironment of multiple myeloma. In Annals of Hematology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00277-024-05843-4
Xue, H.-Y. & Wei, F. (2024). TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-β in the microenvironment of multiple myeloma. Ann Hematol, 103(11), 4351–4362. https://doi.org/10.1007/s00277-024-05843-4
Yi, Z., Ma, T., Liu, J., Tie, W., Li, Y., Bai, J., Li, L. & Zhang, L. (2022). The yin–yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. Front. Immunol., 13, 925266. https://doi.org/10.3389/fimmu.2022.925266
Zhang, H., Liu, M., Xiao, X., Lv, H., Jiang, Y., Li, X., Yuan, T. & Zhao, M. (2022). A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leukemia & Lymphoma, 63(6), 1418–1427.
https://doi.org/10.1080/10428194.2022.2030476
Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front. Immunol., 13, 927153.
https://doi.org/10.3389/fimmu.2022.927153
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y. & Wu, M. (2018). The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. In Acta Pharmaceutica Sinica B (Vol. 8, Issue 4, pp. 539–551). Chinese Academy of Medical Sciences.
https://doi.org/10.1016/j.apsb.2018.03.001
Zhou, X., Rasche, L., Kortüm, K. M., Mersi, J. & Einsele, H. (2023). BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. In Haematologica (Vol. 108, Issue 4, pp. 958–968). NLM (Medline).
https://doi.org/10.3324/haematol.2020.266841
Basudhar, D., Descalzi-Montoya, D., Tang, H., Wang, M., Wu, F., Bergsagel, P. L., Leleu, X., Hosseyni, D., Chaudhry, M., Martin, N. & Thompson, E. G. (2024). Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis. Blood, 144(Supplement 1), 3382–3382.
https://doi.org/10.1182/blood-2024-198740
Beatty, G. L. & Gladney, W. L. (2015). Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 21(4), 687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O’Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., … Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet, 398(10297), 314–324.
https://doi.org/10.1016/S0140-6736(21)00933-8
Botta, C., Mendicino, F., Martino, E. A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A. & Gentile, M. (2021). Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 13(13), 3213.
https://doi.org/10.3390/cancers13133213
Cancer site ranking. (n.d.). Retrieved July 1, 2025, from
https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T. & Kochenderfer, J. N. (2013). B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma. Clinical Cancer Research, 19(8), 2048–2060. https://doi.org/10.1158/1078-0432.CCR-12-2422
Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F. & Asmamaw Dejenie, T. (2022). Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol., 13, 991092.
https://doi.org/10.3389/fimmu.2022.991092
Chen, H., Wang, X., Wang, Y. & Chang, X. (2023). What happens to regulatory T cells in multiple myeloma. Cell Death Discov., 9(1), 468. https://doi.org/10.1038/s41420-023-01765-8
Cheng, Y., Zhang, J., Mu, W., Ye, S., Cheng, J., Zhu, L., Wang, G., Cao, Y., Li, D., Hu, G., Huang, L., Wang, J. & Zhou, J. (2025). Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Molecular Therapy, 33(4), 1535–1551. https://doi.org/10.1016/j.ymthe.2025.02.012
Cho, S. F., Anderson, K. C. & Tai, Y. T. (2018). Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. In Frontiers in Immunology (Vol. 9, Issue AUG). Frontiers Media S.A.
https://doi.org/10.3389/fimmu.2018.01821
Cowan, A. J., Pont, M. J., Sather, B. D., Turtle, C. J., Till, B. G., Libby, E. N., Coffey, D. G., Tuazon, S. A., Wood, B., Gooley, T., Wu, V. Q., Voutsinas, J., Song, X., Shadman, M., Gauthier, J., Chapuis, A. G., Milano, F., Maloney, D. G., Riddell, S. R. & Green, D. J. (2023). γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. The Lancet Oncology, 24(7), 811–822. https://doi.org/10.1016/S1470-2045(23)00246-2
Duan, D. / W. (2021). The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. PubMed.
https://doi.org/10.3389/fimmu.2021.609421
Dytfeld, D., Dhakal, B., Agha, M., Manier, S., Delforge, M., Kuppens, S., Afifi, S., Deraedt, W., Taraseviciute-Morris, A., Schecter, J. M. & al., et. (2021). Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: a Randomized, Phase 3 Study (CARTITUDE-5). Blood, 138, 1835. https://doi.org/10.1182/blood-2021-146210
FDA. (n.d.). Center for Drug Evaluation, Research. FDA approves idecabtagene vicleucel for multiple myeloma [Internet]. U.S. Food and Drug Administration. FDA; 2024.
Feins, S., Kong, W., Williams, E. F., Milone, M. C. & Fraietta, J. A. (2019). An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. In American Journal of Hematology (Vol. 94, Issue S1, pp. S3–S9). Wiley-Liss Inc.
https://doi.org/10.1002/ajh.25418
Fischer, L., Grieb, N., Platzbecker, U., Vucinic, V. & Merz, M. (2024). CAR T cell therapy in multiple myeloma, where are we now and where are we heading for? In European Journal of Haematology (Vol. 112, Issue 1, pp. 19–27). John Wiley and Sons Inc.
https://doi.org/10.1111/ejh.14051
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B. & Kröger, N. (2020). Development of CAR-T cell therapies for multiple myeloma. Leukemia, 34(9), 2317–2332.
https://doi.org/10.1038/s41375-020-0930-x
Garfall, A. L., Cohen, A. D., Lacey, S. F., Tian, L., Hwang, W.-T., Vogl, D. T., Waxman, A., Lancaster, E., Nelson, A. M., Ferthio, R. & al., et. (2019). Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. Blood, 134. https://doi.org/10.1182/blood-2019-131515
Hamieh, M., Dobrin, A., Cabriolu, A., Van Der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., Li, Z., Cunanan, K. M., Huse, M., Hendrickson, R. C., Wang, X., Rivière, I. & Sadelain, M. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568(7750), 112–116.
https://doi.org/10.1038/s41586-019-1054-1
Hillengass, J., Cohen, A. D., Agha, M. E., Delforge, M., Kerre, T., Roeloffzen, W., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M. S., Scheid, C., Anguille, S., Sonneveld, P., Zweegman, S., Schecter, J. M., De Braganca, K. C., Jackson, C. C., Vlummens, P., Varsos, H., … Van De Donk, N. W. C. J. (2023). The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B). Blood, 142(Supplement 1), 1021. https://doi.org/10.1182/blood-2023-178882
Ho, M., Goh, C. Y., Patel, A., Staunton, S., O’Connor, R., Godeau, M. & Bianchi, G. (2020). Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma Myeloma and Leukemia, 20(10), e752–e768.
https://doi.org/10.1016/j.clml.2020.05.026
Jameson, L., Kasper, D., Longo, D., Fauci, A., Hauser, S. & Loscalzo, J. (2018). Harrison Principios de Medicina Interna (L. Jameson, D. Kasper, D. Longo, A. Fauci, S. Hauser, & J. Loscalzo, Eds.; 20a ed., Vol. 1). Mc Graw Hill Education .
Joshua, D. E., Bryant, C., Dix, C., Gibson, J. & Ho, J. (2019). Biology and therapy of multiple myeloma. In Medical Journal of Australia (Vol. 210, Issue 8, pp. 375–380). John Wiley and Sons Inc. https://doi.org/10.5694/mja2.50129
Joshua, D. E., Vuckovic, S., Favaloro, J., Lau, K. H. A., Yang, S., Bryant, C. E., Gibson, J. & Ho, P. J. (2021). Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. Front. Immunol., 12, 620596. https://doi.org/10.3389/fimmu.2021.620596
Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C. & Caers, J. (2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? In Journal of Hematology and Oncology (Vol. 15, Issue 1). BioMed Central Ltd.
https://doi.org/10.1186/s13045-022-01296-2
Leblay, N., Maity, R., Hasan, F. & Neri, P. (2020). Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. In Frontiers in Oncology (Vol. 10). Frontiers Media S.A. https://doi.org/10.3389/fonc.2020.00636
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., Barakat, E., Poorebrahim, M., Sinha, S., McIntyre, J., M.Y. Chan, A., Wilson, H., Kyman, S., Krishnan, A., Landgren, O., … Bahlis, N. J. (2023). Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med, 29(9), 2295–2306. https://doi.org/10.1038/s41591-023-02491-5
Agila Mocha, R. J., Vivanco Ureña, C. I., León Bravo, F. E., & Reyes Carrión , J. P. (2025). Software Educativos para el Proceso de Enseñanza Aprendizaje de Matemáticas en Bachillerato. Ciencia Y Reflexión, 4(2), 1341–1369. https://doi.org/10.70747/cr.v4i2.334
Urquidez Romero , R., Avitia Sánchez, A., Cano Ramírez , D., Jiménez Montes , L. V., Barranco Merino, G. I., & Reyes Ruvalcaba, D. (2025). Programa de Intervención con un Suplemento Multivitamínico para Mejorar el Estado de Nutrición y Anemia en Niños en Condición de Vulnerabilidad Social de Ciudad Juárez Chihuahua. Ciencia Latina Revista Científica Multidisciplinar, 9(3), 8340-8354. https://doi.org/10.37811/cl_rcm.v9i3.18460
Añapa Quiñónez, P. L., Recalde Páez, J. P., Fey Zalamea, C. D., Rivera Quiñónez, E. D., & Acuri Pacheco, D. A. (2025). Estrategias para la Implementación Efectiva del Aprendizaje Híbrido (Blended Learning) en Instituciones Educativas Rurales del Ecuador: Un Análisis Integral. Ciencia Y Reflexión, 4(2), 1160–1184. https://doi.org/10.70747/cr.v4i2.325
Tenesaca Canchignia , D. C., Canchignia Bonilla, E. L., Remache Guamán, N. V., Guamán Sagñay , H. P., & Hualcopo Duchicela, U. E. (2025). Guía para padres con respecto al uso de dispositivos móviles el niños de nivel preparatorio. Arandu UTIC, 12(2), 287–307. https://doi.org/10.69639/arandu.v12i2.925
Araujo García, D., Chang Espinosa , O. Y., & Pérez Vázquez , D. (2025). Consultoría Estratégica para Mipymes: Estudio de Mercado para Impulsar el Desarrollo Regional en Perote, Veracruz. Estudios Y Perspectivas Revista Científica Y Académica , 5(3), 27–45. https://doi.org/10.61384/r.c.a.v5i3.1328
Simbaña Cabrera, H. A., Haro Jácome, O. F., García-Romero , C. A., & Analuisa García , P. S. (2025). La titulación rural, una propuesta colectiva que evidencia la realidad educativa de las escuelas multigrado. Emergentes - Revista Científica, 5(2), 1–14. https://doi.org/10.60112/erc.v5.i2.385
Cortés Viveros, N., Hernández García, R. A., Galván Sarabia, A., Olivares Galvan, H. R., & Texon Olguin, O. A. (2025). En Busca del Modelo Ideal para Determinar las Variables que Explican el Tiempo de Desempleo en Buscadores Xalapeños. Estudios Y Perspectivas Revista Científica Y Académica , 5(3), 65–81. https://doi.org/10.61384/r.c.a.v5i3.1332
Bernal Parraga, A. P., Salazar Véliz , E. T., Zambrano Lamilla, L. M., Espinoza Jaramillo , S. G., Morales García , C. S., Shinger Hipatia, N. S., & Zapata Calderón , S. J. (2025). Innovaciones Didácticas para Lengua y Literatura Basadas en el Aprendizaje Personalizado y Colaborativo . Revista Científica De Salud Y Desarrollo Humano , 6(2), 01–32. https://doi.org/10.61368/r.s.d.h.v6i2.574
Sabando Suárez, A. A., Vega Guamangate, J. M., García Gallirgos, V. J., & Mora Carpio, W. T. (2025). Impacto del Gasto Social en el Índice de Desarrollo Humano en Ecuador. periodo 2001-2023. Revista Veritas De Difusão Científica, 6(2), 1593–1633. https://doi.org/10.61616/rvdc.v6i2.707
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., De Re, V., Argentiero, A., Silvestris, N., Vacca, A. & Racanelli, V. (2020). Actors on the Scene: Immune Cells in the Myeloma Niche. Front. Oncol., 10, 599098.
https://doi.org/10.3389/fonc.2020.599098
Li, H., Li, J., Wu, J., Shi, Z., Gao, Y., Song, W., Li, J., Li, Z. & Zhang, M. (2023). A second-generation CD38-CAR-T cell for the treatment of multiple myeloma. Cancer Medicine, 12(9), 10804–10815. https://doi.org/10.1002/cam4.5818
Lu, J. & Jiang, G. (2022). The journey of CAR-T therapy in hematological malignancies. Mol Cancer, 21(1), 194. https://doi.org/10.1186/s12943-022-01663-0
Mancuso, K., Barbato, S., Talarico, M., Tacchetti, P., Zamagni, E. & Cavo, M. (2025). Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. Expert Opinion on Biological Therapy, 25(1), 27–46.
https://doi.org/10.1080/14712598.2024.2433518
Mann, H. & Comenzo, R. L. (2022). Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. In OncoTargets and Therapy (Vol. 15, pp. 799–813). Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S305429
Munshi, N. C. / A. (2021). Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. PubMed. https://doi.org/10.1056/NEJMoa2024850
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G. & Gangemi, S. (2017). Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. In Mediators of Inflammation (Vol. 2017). Hindawi Limited.
https://doi.org/10.1155/2017/1852517
Nakamura, K., Smyth, M. J. & Martinet, L. (2020). Cancer immunoediting and immune dysregulation in multiple myeloma. Blood, 136(24), 2731–2740. https://doi.org/10.1182/blood.2020006540
Nasiri, F., Asaadi, Y., Mirzadeh, F., Abdolahi, S., Molaei, S., Gavgani, S. P. & Rahbarizadeh, F. (2024). Updates on CAR T cell therapy in multiple myeloma. Biomark Res, 12(1), 102.
https://doi.org/10.1186/s40364-024-00634-5
O’Neal, J., Ritchey, J. K., Cooper, M. L., Niswonger, J., Sofía González, L., Street, E., Rettig, M. P., Gladney, S. W., Gehrs, L., Abboud, R., Prior, J. L., Haas, G. J., Jayasinghe, R. G., Ding, L., Ghobadi, A., Vij, R. & DiPersio, J. F. (2022). CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia, 36(6), 1625–1634.
https://doi.org/10.1038/s41375-022-01559-4
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V. & Ajebo, G. H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Medical Sciences, 9(1), 3. https://doi.org/10.3390/medsci9010003
Pont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J., Salter, A. I., Hudecek, M., Comstock, M. L., Rajan, A., Patel, B. K. R., Voutsinas, J. M., Wu, Q., Liu, L., Cowan, A. J., Wood, B. L., Green, D. J. & Riddell, S. R. (2019). g-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
http://ashpublications.org/blood/article-pdf/134/19/1585/1505398/bloodbld2019000050.pdf
Poojary, R., Song, A., Song, B., Song, C., Wang, L. & Song, J. (2023). Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review). Mol Clin Oncol, 19(6), 95. https://doi.org/10.3892/mco.2023.2691
Radhakrishnan, V., Golla, U. & Kudva, A. K. (2024). Role of Immune Cells and Immunotherapy in Multiple Myeloma. Life, 14(4), 461. https://doi.org/10.3390/life14040461
Radhakrishnan, S. V, Luetkens, T., Scherer, S. D., Davis, P., Vander Mause, E. R., Olson, M. L., Yousef, S., Panse, J., Abdiche, Y., Li, K. D., Miles, R. R., Matsui, W., Welm, A. L. & Atanackovic, D. (2020). CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun, 11(1), 798. https://doi.org/10.1038/s41467-020-14619-z
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., Lam, L.-P., Morgan, R. A., Friedman, K., Massaro, M., Wang, J., Russotti, G., Yang, Z., Campbell, T., Hege, K., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 380(18), 1726–1737. https://doi.org/10.1056/nejmoa1817226
Ramesh, P., Hui, H. Y. L., Brownrigg, L. M., Fuller, K. A. & Erber, W. N. (2023). Chimeric antigen receptor T-cells: Properties, production, and quality control. In International Journal of Laboratory Hematology (Vol. 45, Issue 4, pp. 425–435). John Wiley and Sons Inc.
https://doi.org/10.1111/ijlh.14121
Rapoport, A. P. (2015). Myeloma escape from immunity: an “inside” job. Blood, 126(12), 1401–1403.
https://doi.org/10.1182/blood-2015-07-659490
Rickert, R. C., Jellusova, J. & Miletic, A. V. (2011). Signaling by the tumor necrosis factor receptor superfamily in B‐cell biology and disease. Immunological Reviews, 244(1), 115–133.
https://doi.org/10.1111/j.1600-065X.2011.01067.x
Rodríguez Otero, P., Ailawadhi, S., Arnulf, B., Patel, K. K., Cavo, M., Nooka, A. K., Manier, S., Callander, N. S., Costa, L., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Weum Abrahamsen, I., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N. S., … Giralt, S. A. (2023). The 65th ASH Annual Meeting Abstracts ORAL ABSTRACTS 705.CELLULAR IMMUNOTHERAPIES: LATE PHASE AND COMMERCIALLY AVAILABLE THERAPIES Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3. In Blood (Vol. 142).
Sadelain, M., Brentjens, R. & Rivière, I. (2013). The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discovery, 3(4), 388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Samur, M. K., Fulciniti, M., Aktas Samur, A., Bazarbachi, A. H., Tai, Y.-T., Prabhala, R., Alonso, A., Sperling, A. S., Campbell, T., Petrocca, F., Hege, K., Kaiser, S., Loiseau, H. A., Anderson, K. C. & Munshi, N. C. (2021). Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun, 12(1), 868.
https://doi.org/10.1038/s41467-021-21177-5
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández De Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., Van De Donk, N. W. C. J., Dytfeld, D., Sidana, S., … Einsele, H. (2023). Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379
Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. (2020). B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. In Leukemia (Vol. 34, Issue 4, pp. 985–1005). Springer Nature. https://doi.org/10.1038/s41375-020-0734-z
Sheykhhasan, M., Ahmadieh-Yazdi, A., Vicidomini, R., Poondla, N., Tanzadehpanah, H., Dirbaziyan, A., Mahaki, H., Manoochehri, H., Kalhor, N. & Dama, P. (2024). CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther, 31(5), 667–686.
https://doi.org/10.1038/s41417-024-00750-2
Simon, S. & Riddell, S. R. (2020). Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. Blood Cancer Discovery, 1(2), 130–133. https://doi.org/10.1158/2643-3230.BCD-20-0122
Sun, C., Mahendravada, A., Ballard, B., Kale, B., Ramos, C., West, J., Maguire, T., Mckay, K., Lichtman, E., Tuchman, S., Dotti, G. & Savoldo, B. (2019). Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. In Oncotarget (Vol. 10, Issue 24). www.oncotarget.com
Swan, D., Madduri, D. & Hocking, J. (2024). CAR-T cell therapy in Multiple Myeloma: current status and future challenges. Blood Cancer J., 14(1), 206. https://doi.org/10.1038/s41408-024-01191-8
Teoh, P. J. & Chng, W. J. (2021). CAR T-cell therapy in multiple myeloma: more room for improvement. In Blood Cancer Journal (Vol. 11, Issue 4). https://doi.org/10.1038/s41408-021-00469-5
Usmani, S. Z., Berdeja, J. G., Truppel-Hartmann, A., Casadebaig, M.-L., Wortman-Vayn, H., Shelat, S. G., Novick, S. & Shah, N. (2020). KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma. Blood, 136(Supplement 1), 18–19. https://doi.org/10.1182/blood-2020-139009
Wang, C., Wang, W., Wang, M., Deng, J., Sun, C., Hu, Y. & Luo, S. (2024). Different evasion strategies in multiple myeloma. Front. Immunol., 15, 1346211.
https://doi.org/10.3389/fimmu.2024.1346211
Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., Lim, L., Wong, C. W., Chang, W.-C., Thomas, S. H., Sanchez, J. F., Yang, L., Brown, C. E., Pichiorri, F., Htut, M., Krishnan, A. Y. & Forman, S. J. (2018). Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 24(1), 106–119. https://doi.org/10.1158/1078-0432.CCR-17-0344
Wu, S.-Y., Fu, T., Jiang, Y.-Z. & Shao, Z.-M. (2020). Natural killer cells in cancer biology and therapy. Mol Cancer, 19(1), 120. https://doi.org/10.1186/s12943-020-01238-x
Wudhikarn, K., Mailankody, S. & Smith, E. L. (2020). Future of CAR T cells in multiple myeloma. Hematology, 2020(1), 272–279. https://doi.org/10.1182/hematology.2020000111
Xue, H. Y. & Wei, F. (2024). TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-β in the microenvironment of multiple myeloma. In Annals of Hematology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00277-024-05843-4
Xue, H.-Y. & Wei, F. (2024). TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-β in the microenvironment of multiple myeloma. Ann Hematol, 103(11), 4351–4362. https://doi.org/10.1007/s00277-024-05843-4
Yi, Z., Ma, T., Liu, J., Tie, W., Li, Y., Bai, J., Li, L. & Zhang, L. (2022). The yin–yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. Front. Immunol., 13, 925266. https://doi.org/10.3389/fimmu.2022.925266
Zhang, H., Liu, M., Xiao, X., Lv, H., Jiang, Y., Li, X., Yuan, T. & Zhao, M. (2022). A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leukemia & Lymphoma, 63(6), 1418–1427.
https://doi.org/10.1080/10428194.2022.2030476
Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front. Immunol., 13, 927153.
https://doi.org/10.3389/fimmu.2022.927153
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y. & Wu, M. (2018). The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. In Acta Pharmaceutica Sinica B (Vol. 8, Issue 4, pp. 539–551). Chinese Academy of Medical Sciences.
https://doi.org/10.1016/j.apsb.2018.03.001
Zhou, X., Rasche, L., Kortüm, K. M., Mersi, J. & Einsele, H. (2023). BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. In Haematologica (Vol. 108, Issue 4, pp. 958–968). NLM (Medline).
https://doi.org/10.3324/haematol.2020.266841
Publicado
2025-09-10
Cómo citar
Abril Bravo , C. L. (2025). Terapia con Células Car-t Anti-bcma ¿Resuelve la Evasión Inmune en el Mieloma Múltiple?. Ciencia Latina Revista Científica Multidisciplinar, 9(4), 6851-6879. https://doi.org/10.37811/cl_rcm.v9i4.19286
Número
Sección
Ciencias de la Salud
Derechos de autor 2025 Carmita Liliana Abril Bravo
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
